The dissemination of carbapenemaseproducing Enterobacteriaceae (CPE) is a global public health challenge. Early and accurate detection of CPE, as well as prompt infection prevention and control measures, are required to minimize the risk of dissemination in healthcare settings (CDC, 2009 ).
In October 2014, Escherichia coli isolated from a rectal swab was submitted by Hospital 1 to our CPE reference service in Galway for confirmation of carbapenemase production. The isolate was identified as a possible CPE through screening using in-house ertapenem-cloxacillin-zinccontaining MacConkey agar, which is a modification of the SUPERCARBA medium (Girlich et al., 2013 ). The isolate also tested positive in the referring hospital laboratory for an OXA-48-like carbapenemase using a commercial assay (Check-Direct CPE Real-Time PCR; Check-Points). Tests in our reference service confirmed that the isolate was resistant to ertapenem (MIC 4 Enhanced training and education of the unit's healthcare staff on the importance of adherence to recommended infection control measures for multidrug-resistant organisms including CPE were instituted. Rectal screening using selective agar (Brilliance CRE agar; Oxoid) of other patients epidemiologically linked to the two cases was performed. Brilliance CRE agar was found to be of comparable sensitivity to SUPERCARBA medium, and possibly more sensitive than CHROMagar KPC medium, in the detection of isolates producing OXA-181, although the number of such isolates investigated in the study was small (Girlich et al., 2013 (Potron et al., 2011 (Potron et al., , 2013 . The OXA-181 enzyme is reported mainly in Klebsiella pneumoniae and predominantly in Asian and Middle Eastern countries (Balm et al., 2013; Potron et al., 2011; Ruppé et al., 2014; Williamson et al., 2011) , although OXA-181-producing E. coli originating from Nigeria and the (Ruppé et al., 2014; Williamson et al., 2011) .
This report highlights the inherent potential problem with in-house and commercial molecular assays in the failure to detect newer variants of existing carbapenemase families, unless they share sufficient sequence similarity with known variants. Recent reports have highlighted the potential for false-negative results for OXA-181 in Enterobacteriaceae with early versions of the GeneXpert Carba-R and eazyplex SuperBug complete kits, although both assays have since been updated to improve detection of this and related variants (Decousser et al., 2015; Findlay et al., 2015) . This report reiterates the consequences of non-detection. 
